In vivo experiments showed that USP19 silencing reduces tumorigenicity and delays tumor onset and growth, and the opposite was observed upon wild type USP19 overexpression (but not when overexpressing a catalytically dead mutant, or a cytoplasmic version of USP19). The gene discussed is USP19; the disease is neoplasm.